Evidence map›Paper›PMID 38807632›Full record

ArticlePNAS nexus2024

Oral delivery of nanomedicine for genetic kidney disease.

Yi Huang, Jonathan Wang, Valeria Mancino, Jessica Pham, Colette O'Grady, Hui Li, Kairui Jiang, Deborah Chin, Christopher Poon, Pei-Yin Ho and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PNAS nexus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Combination siRNA delivery as a therapeutic strategy for ADPKD.bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yi HuangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Jonathan WangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.ORCID https://orcid.org/0000-0003-3184-2705
Valeria MancinoDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Jessica PhamDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Colette O'GradyDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Hui LiDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Kairui JiangDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.ORCID https://orcid.org/0000-0002-0166-0209
Deborah ChinDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Christopher PoonDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.ORCID https://orcid.org/0000-0002-9797-7162
Pei-Yin HoDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Georgina GyarmatiDepartment of Physiology and Neuroscience, and Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA 90033, USA.
János Peti-PeterdiDepartment of Physiology and Neuroscience, and Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, CA 90033, USA.
Kenneth R HallowsDepartment of Medicine, Division of Nephrology and Hypertension, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Eun Ji ChungDepartment of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.ORCID https://orcid.org/0000-0002-7726-5555

Funding

Multiphoton imaging of the juxtaglomerular apparatusR01DK064324 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2004 to 2025
$1.2M
NIDDK NIH HHS DP2 DK121328NIDDK NIH HHS R01 DK064324NIH HHS S10 OD021833
6 · The paper itself

Abstract

Chronic and genetic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD) have few therapeutic options, and clinical trials testing small molecule drugs have been unfavorable due to low kidney bioavailability and adverse side effects. Although nanoparticles can be designed to deliver drugs directly to the diseased site, there are no kidney-targeted nanomedicines clinically available, and most FDA-approved nanoparticles are administered intravenously which is not ideal for chronic diseases. To meet these challenges of chronic diseases, we developed a biomaterials-based strategy using chitosan particles (CP) for oral delivery of therapeutic, kidney-targeting peptide amphiphile micelles (KMs). We hypothesized that encapsuling KMs into CP would enhance the bioavailability of KMs upon oral administration given the high stability of chitosan in acidic conditions and mucoadhesive properties enabling absorption within the intestines. To test this, we evaluated the mechanism of KM access to the kidneys via intravital imaging and investigated the KM biodistribution in a porcine model. Next, we loaded KMs carrying the ADPKD drug metformin into CP (KM-CP

Indexed as

chronic diseasedrug deliverykidney targetingnanomedicineoral delivery

Identifiers

PMID38807632
PMCPMC11131023

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.